Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke

Completed · Phase 3

Conditions studied: Ischemic Cerebral Infarction

In brief

1. Clarify novel systemic and local inflammatory mechanisms underlying the cross talk between brain and heart ischemic states, 2. Investigate the new aspects of NAC beyond traditional therapy, in cerebral and myocardial ischemic conditions, both in animal models and clinical cases.

Key facts

Study ID

NCT07749287

Run by

Helwan University

People needed

121

Starts

2021-06-01

Expected to finish

2024-03-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age above 18 years
• AIS patients admitted into stroke unit
• Onset within 48 hours
• Glasgow coma scale (GCS) ≥ 8
• Out of window or contraindicated for thrombolytics
• Not arrested before

You may not qualify if…

• Age below 18 years
• Cerebral haemorrhage
• Dural sinus thrombosis
• Glasgow coma scale (GCS) < 8
• Patients received thrombolytic
• Post arrest

Where it is running

• Stroke Unit, Neurology Department, Kasr Al Ainy, Cairo University Hospital — Cairo, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.